Back to Directory Rachel Scott Email rachel.k.scott@medstar.net Phone 617-513-9930 Institution MedStar Health Research Institute/Washington Hospital Center Request an Update Affiliated Studies IMPAACT 2050: Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn
IMPAACT 2050: Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn
